Patel Vipul P, Bong Matthew, Di Cesare Paul E
Department of Orthopaedic Surgery, New York University Hospital for Joint Diseases, New York, New York, USA.
Am J Orthop (Belle Mead NJ). 2007 May;36(5):255-60.
Heparin-induced thrombocytopenia (HIT) and heparin induced thrombocytopenia with thrombosis (HITT) ar rare complications associated with use of unfractionate heparin (UFH) or low-molecular-weight heparin (LMWH) HIT is a benign clinical condition characterized by a mil drop in platelet count with no clinical significance. HIT is an immune-mediated reaction associated with a wide spread "hypercoagulable" state resulting in arterial an venous thrombosis. There is a higher incidence of HIT with UFH use than with LMWH use. Orthopedic surger patients are at higher risk for developing HITT than are patients who receive prophylactic heparin for cardiovascular surgery or medical reasons. Therapy for patients suspected of having HITT should begin with immedi ate discontinuation of heparin in any form followed by pharmacologic inhibition with thrombin (e.g., recombinant hirudin [lepirudin], argatroban, danaparoid sodium).
肝素诱导的血小板减少症(HIT)和肝素诱导的血小板减少症伴血栓形成(HITT)是与使用普通肝素(UFH)或低分子量肝素(LMWH)相关的罕见并发症。HIT是一种良性临床病症,其特征为血小板计数轻度下降且无临床意义。HIT是一种免疫介导的反应,与广泛的“高凝”状态相关,可导致动静脉血栓形成。使用UFH时HIT的发生率高于使用LMWH时。骨科手术患者发生HITT的风险高于因心血管手术或医疗原因接受预防性肝素治疗的患者。疑似患有HITT的患者的治疗应首先立即停用任何形式的肝素,然后用凝血酶进行药物抑制(例如重组水蛭素[lepirudin]、阿加曲班、达那肝素钠)。